deltatrials
Recruiting OBSERVATIONAL NCT06950697

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Sponsor: Beijing Chao Yang Hospital

Conditions Arterial Thromboembolism Immune Checkpoint Inhibitors (ICIs) Lung Cancer Venous Thromboembolism
Updated 3 times since 2025 Last updated: Apr 26, 2026 Started: Jan 1, 2019 Primary completion: Dec 31, 2026 Completion: Dec 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Arterial Thromboembolism and Immune Checkpoint Inhibitors (ICIs) and is currently actively recruiting participants. Beijing Chao Yang Hospital leads this study, which shows 3 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2025 – ~Sep 2025 · 4 months · monthly snapshotRecruiting~Sep 2025 – ~May 2026 · 8 months · monthly snapshotRecruitingMay 4, 2026 – present · 2 months · daily APIRecruiting

Change History

3 versions recorded

  1. May 4, 2026 — Present [daily]

    Recruiting

  2. Sep 2025 — May 2026 [monthly]

    Recruiting

  3. May 2025 — Sep 2025 [monthly]

    Recruiting

    First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are: 1. What is the real-world incidence of VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 2. What are the risk factors and biomarkers for VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 3. What is the impact of VTE/ATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors? Researchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE/ATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events to provide guidance for precision prevention and treatment in clinical practice.

Contact Information

Sponsor contact:
  • Beijing Chao Yang Hospital
  • Capital Medical University
  • China-Japan Friendship Hospital
  • The First Affiliated Hospital of Zhengzhou University
  • The Fourth Hospital of Inner Mongolia Autonomous Region
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations